The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) commissioned Charles River Associates to review the evidence on the value of innovation for diabetes in middle-income countries (MICs) and test the extent to which the experience of these countries is aligned with the experience of high-income countries (HICs). The report provides an overview of the therapeutic and wider societal value of type-2 diabetes (T2D) medicines in China. China is the MIC with the largest number of people with T2D and has recognized T2D to be an escalating challenge.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...